Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows a 25% revenue increase, which is positive, but the company still reported a net loss of $12.7 million. R&D expenses decreased, which may indicate cost-cutting, while SG&A expenses increased, suggesting investment in growth. Cash reserves decreased, potentially raising liquidity concerns. The absence of strategic initiatives, operational updates, and return discussions, coupled with unclear Q&A responses, leads to a neutral sentiment. Given the market cap, stock price movement is likely to be neutral in the next two weeks.
Key Financial Performance
Revenue $45.3 million, a 25% increase year-over-year, driven by strong sales growth in North America and Europe.
Net Loss $12.7 million, an improvement from $15.4 million in the prior year, attributed to increased revenue and cost management.
Research and Development Expenses $18.2 million, a 10% decrease year-over-year, due to streamlined operations and prioritization of key projects.
Selling, General, and Administrative Expenses $20.5 million, a 5% increase year-over-year, reflecting investments in commercial infrastructure.
Cash and Cash Equivalents $210 million, a decrease from $230 million in the prior year, primarily due to operational expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America Yann
CEO Chien
Capital Markets
Chien Executive
Citigroup Inc
Communications Meeker
Corinne Jenkins
Division Corinne
Division Derek
Division EDT
Division Samantha
Division Stringer
Division Ulz
Division Walter
EDT Ladies
Executive VP
Hunter Smith
Inc Research
International Hunter
Jenkins Goldman
LLC Research
Ladies gentleman
Markets Research
Mazabraud Executive
Meeker Chairman
Needham LLC
RBC Capital
Research Division
Rhythm
Securities LLC
VP Head
RYTM Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary shows a 25% revenue increase, which is positive, but the company still reported a net loss of $12.7 million. R&D expenses decreased, which may indicate cost-cutting, while SG&A expenses increased, suggesting investment in growth. Cash reserves decreased, potentially raising liquidity concerns. The absence of strategic initiatives, operational updates, and return discussions, coupled with unclear Q&A responses, leads to a neutral sentiment. Given the market cap, stock price movement is likely to be neutral in the next two weeks.
Kolibri Global Energy Inc. (KEI:CA) Q4 2025 Earnings Call Transcript
Positive3-20
The earnings call reveals strong financial performance with significant year-over-year growth in revenue, net income, and EBITDA, driven by higher production and cost efficiencies. Although forward-looking statements carry risks, the positive financial results are likely to outweigh uncertainties in the short term. The lack of strategic updates and shareholder return discussions is a minor concern, but the financial metrics suggest a positive stock price movement over the next two weeks.
RYTM Slides
Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch2026-05-05
Rhythm Pharma Q4 2025 slides: revenue beats as HO launch nears2026-02-26
Rhythm Pharmaceuticals Q2 2025 slides: Revenue jumps 29%, obesity drugs show promise2025-08-05
Rhythm Pharmaceuticals Q1 2025 slides: Revenue grows 45% as HO program advances2025-05-07
RYTM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
